Sun Pharmaceutical Industries Limited has filed a regulatory disclosure under SEBI Listing Regulation 30 to announce the establishment of an endowed professorship in dermatology. The company is providing a $2.5 million endowment to the Icahn School of Medicine at Mount Sinai to establish the Sun Professorship in Dermatology, which will fund academic leadership in perpetuity.

The professorship is based within the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai. Dr. Mark G. Lebwohl, MD, has been installed as the inaugural professor at a ceremony held on October 6, 2026, at Hatch Auditorium at The Mount Sinai Hospital in New York.

Purpose and Rationale

The endowment aims to advance dermatologic care through supporting research, education, and mentorship. The professorship will help translate emerging knowledge into better patient care and prepare future leaders in the field. Sun Pharma describes this as reflecting their "long-term commitment to fostering the academic leadership needed to pursue new ideas and strengthen care for generations to come."

Key Personnel

  • Dr. Mark G. Lebwohl serves as Dean for Clinical Therapeutics at the Icahn School of Medicine at Mount Sinai and Professor and Chairman Emeritus of the Kimberly and Eric J. Waldman Department of Dermatology
  • Dr. Ahmad Naim, MD, Senior Vice President and Chief Medical Officer, North America at Sun Pharma, commented on the company's commitment to dermatology care
  • Dr. Emma Guttman, MD, PhD, Waldman Professor and System Chair of the Kimberly and Eric J. Waldman Department of Dermatology
  • Dr. Eric J. Nestler, MD, PhD, Dean of the Icahn School of Medicine at Mount Sinai and Chief Scientific Officer of the Mount Sinai Health System

Company Context

Sun Pharma identifies itself as the second-largest pharmaceutical dermatology company in the U.S. by prescription volume and emphasizes its commitment to advancing patient care through scientific innovation, education, and partnerships. The company's Global Innovative Medicines portfolio accounts for about 22% of company sales and spans innovative products in dermatology, ophthalmology, and oncodermatology.

Financial Impact

The endowment amount of $2.5 million represents a one-time philanthropic contribution. No ongoing financial obligations or operational impacts are disclosed.